NASDAQ •
Healthcare •
Drug Manufacturers - Specialty & Generic •
Quote as of 09/04/2026 16:00
Company Profile
IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
ExchangeNASDAQ
Market Capitalization1,814.41 mln
Float161 mln
Earnings Date11/11/2026
Piotroski F-Score
2
/ 9
Weak
Beneish M-Score
-3.05
Reliable
1-Year Forecast
6.00
Modest upside
Relative Strength
97
/ 100
Top performer
Debt / Equity
-7.58
Negative equity
Pre-Tax Margin
-7%
Marginally loss-making
Business Description
Founded in 2013 and headquartered in Luxembourg, Alvotech develops and manufactures biosimilar medicines designed to be more affordable alternatives to established biologic drugs. The company's portfolio targets a range of serious conditions, including inflammatory diseases such as rheumatoid arthritis, Crohn's disease, and psoriasis, as well as eye conditions, bone disorders, certain cancers, and respiratory allergies. Alvotech supplies these medicines to patients across the world through its subsidiaries and commercial partners.
